Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040003/S022

Exablate 2000 System Magnetic Resonance Guided Focused Ultrasound Ablation of Uterine Fibroids

Insightec, Ltd. · Decision date Jul 23, 2025

FDA DECISIONP040003/S022

What did the FDA approve?

FDA records P040003/S022 as a supplement to PMA P040003, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 23, 2025.

FDA approval order statement

You proposed to change the total number of enrolled subjects from 200 to 198. Based upon the information submitted, the PMA supplement is approved.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Obstetrics/Gynecology
Decision date
Jul 23, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P040003/S022
Regulatory pathway
PMA supplement
Product code
NRZ
Decision code
APPR
Decision date
Jul 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation system, high intensity focused ultrasound (HIFU), MR-guided.

Product code
NRZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040003/S022 received

    Application receipt date recorded by FDA.

  2. P040003/S022 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P040003. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Insightec, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4851 Lbj Frwy, Suite 400, Dallas, TX, 75244

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records